|
Israel's MediWound signs
$112 million deal in U.S. for burn treatment
Send a link to a friend
[September 30, 2015] JERUSALEM
(Reuters) - Israel-based MediWound has signed a five-year, $112 million
contract with the U.S. authority that handles public health medical
emergencies to further develop and buy the company's drug treatment for
severe burns.
|
|
 Investment group Clal Biotechnology, which has a 45 percent stake in
MediWound, said in a statement that the deal with the Biomedical
Advanced Research and Development Authority would raise preparedness
for mass-casualty incidents.
The U.S. body would also help MediWound get approval for its drug
NexoBrid, a topical treatment that removes damaged tissue, from the
Food and Drug Administration, Clal said.
Clal's shares were up 18.6 percent in Tel Aviv in midday trading.
(Reporting by Ari Rabinovitch)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
